Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics ...

Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains 'Buy' with 22% upside potential. Read ...

Sun Pharma share price today reached ₹1,651.80, a 2.50% rise from its last close of ₹1,611.50. The rise is despite the ...

Sun Pharmaceutical Industries Ltd has entered into an agreement to acquire US-based immunotherapy and targeted oncology ...

This came to pass after a landmark acquisition of US-based biotech company Checkpoint Therapeutics. Sun Pharma acquired the Massachusetts-based company for a staggering USD 355 million or about Rs ...

ICICI Securities is bullish on Sun Pharmaceutical Industries recommended buy rating on the stock with a target price of Rs 1895 in its research report dated March 11, 2025.

Vikas Khot Sun Pharma to acquire cancer drug maker Checkpoint for $355 million. Sun Pharmaceutical Industries has agre ...

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This ...

On March 9, 2023, Checkpoint announced the deal with Sun Pharma, under which shareholders will receive $4.10 per share in cash (or a total of $355 million). if cosibelimab receives EU approval within ...

Sun Pharma has acquired Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with the ...